374 related articles for article (PubMed ID: 24756955)
1. Small molecule compounds targeting the p53 pathway: are we finally making progress?
Yu X; Narayanan S; Vazquez A; Carpizo DR
Apoptosis; 2014 Jul; 19(7):1055-68. PubMed ID: 24756955
[TBL] [Abstract][Full Text] [Related]
2. A balancing act: using small molecules for therapeutic intervention of the p53 pathway in cancer.
Miller JJ; Gaiddon C; Storr T
Chem Soc Rev; 2020 Oct; 49(19):6995-7014. PubMed ID: 32869798
[TBL] [Abstract][Full Text] [Related]
3. Mutant p53 reactivation by small molecules makes its way to the clinic.
Bykov VJ; Wiman KG
FEBS Lett; 2014 Aug; 588(16):2622-7. PubMed ID: 24768524
[TBL] [Abstract][Full Text] [Related]
4. Tumor suppressor p53: Biology, signaling pathways, and therapeutic targeting.
Hernández Borrero LJ; El-Deiry WS
Biochim Biophys Acta Rev Cancer; 2021 Aug; 1876(1):188556. PubMed ID: 33932560
[TBL] [Abstract][Full Text] [Related]
5. Awakening the "guardian of genome": reactivation of mutant p53.
Binayke A; Mishra S; Suman P; Das S; Chander H
Cancer Chemother Pharmacol; 2019 Jan; 83(1):1-15. PubMed ID: 30324219
[TBL] [Abstract][Full Text] [Related]
6. Identification of novel p53 pathway activating small-molecule compounds reveals unexpected similarities with known therapeutic agents.
Peltonen K; Colis L; Liu H; Jäämaa S; Moore HM; Enbäck J; Laakkonen P; Vaahtokari A; Jones RJ; af Hällström TM; Laiho M
PLoS One; 2010 Sep; 5(9):e12996. PubMed ID: 20885994
[TBL] [Abstract][Full Text] [Related]
7. Small molecule agents targeting the p53-MDM2 pathway for cancer therapy.
Wang W; Hu Y
Med Res Rev; 2012 Nov; 32(6):1159-96. PubMed ID: 23059763
[TBL] [Abstract][Full Text] [Related]
8. Small Molecules Targeting Mutant P53: A Promising Approach for Cancer Treatment.
Lopes EA; Gomes S; Saraiva L; Santos MMM
Curr Med Chem; 2019; 26(41):7323-7336. PubMed ID: 30444195
[TBL] [Abstract][Full Text] [Related]
9. Targeting p53-MDM2 Interaction Using Small Molecule Inhibitors and the Challenges Needed to be Addressed.
Zanjirband M; Rahgozar S
Curr Drug Targets; 2019; 20(11):1091-1111. PubMed ID: 30947669
[TBL] [Abstract][Full Text] [Related]
10. Restoration of p53 to limit tumor growth.
Wang W; El-Deiry WS
Curr Opin Oncol; 2008 Jan; 20(1):90-6. PubMed ID: 18043262
[TBL] [Abstract][Full Text] [Related]
11. Recent Synthetic Approaches towards Small Molecule Reactivators of p53.
Silva JL; Lima CGS; Rangel LP; Ferretti GDS; Pauli FP; Ribeiro RCB; da Silva TB; da Silva FC; Ferreira VF
Biomolecules; 2020 Apr; 10(4):. PubMed ID: 32326087
[TBL] [Abstract][Full Text] [Related]
12. Restoring guardianship of the genome: Anticancer drug strategies to reverse oncogenic mutant p53 misfolding.
Babikir HA; Afjei R; Paulmurugan R; Massoud TF
Cancer Treat Rev; 2018 Dec; 71():19-31. PubMed ID: 30336366
[TBL] [Abstract][Full Text] [Related]
13. Spiro-oxindoles as a Promising Class of Small Molecule Inhibitors of p53-MDM2 Interaction Useful in Targeted Cancer Therapy.
Gupta AK; Bharadwaj M; Kumar A; Mehrotra R
Top Curr Chem (Cham); 2017 Feb; 375(1):3. PubMed ID: 27943171
[TBL] [Abstract][Full Text] [Related]
14. The p53 pathway as a target in cancer therapeutics: obstacles and promise.
Mandinova A; Lee SW
Sci Transl Med; 2011 Jan; 3(64):64rv1. PubMed ID: 21209413
[TBL] [Abstract][Full Text] [Related]
15. Targeting mutant p53 for cancer therapy: direct and indirect strategies.
Hu J; Cao J; Topatana W; Juengpanich S; Li S; Zhang B; Shen J; Cai L; Cai X; Chen M
J Hematol Oncol; 2021 Sep; 14(1):157. PubMed ID: 34583722
[TBL] [Abstract][Full Text] [Related]
16. Therapeutic targeting of p53 by small molecules.
Selivanova G
Semin Cancer Biol; 2010 Feb; 20(1):46-56. PubMed ID: 20206268
[TBL] [Abstract][Full Text] [Related]
17. Wild type p53 reactivation: from lab bench to clinic.
Selivanova G
FEBS Lett; 2014 Aug; 588(16):2628-38. PubMed ID: 24726725
[TBL] [Abstract][Full Text] [Related]
18. Targeting mutant p53 for efficient cancer therapy.
Bykov VJN; Eriksson SE; Bianchi J; Wiman KG
Nat Rev Cancer; 2018 Feb; 18(2):89-102. PubMed ID: 29242642
[TBL] [Abstract][Full Text] [Related]
19. Small-molecule inhibitors of MDM2 as new anticancer therapeutics.
Dickens MP; Fitzgerald R; Fischer PM
Semin Cancer Biol; 2010 Feb; 20(1):10-8. PubMed ID: 19897042
[TBL] [Abstract][Full Text] [Related]
20. Reactivation of mutant p53 by capsaicin, the major constituent of peppers.
Garufi A; Pistritto G; Cirone M; D'Orazi G
J Exp Clin Cancer Res; 2016 Sep; 35(1):136. PubMed ID: 27599722
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
